- Ampio Pharmaceuticals (NYSE:AMPE) is down 11% premarket on the heels of its announcement that the FDA will require a new clinical trial evaluating lead candidate Ampion in patients with knee osteoarthritis to support a marketing application.
- The company intends to file its Special Protocol Assessment (SPA) for the 150-subject study in the near future. Its design will allow for the expansion of enrollment to 300 if necessary.
FDA requires additional study of Ampio Pharma's Ampion to support marketing application; shares down 11% premarket
Recommended For You
About AMPE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AMPE | - | - |
Ampio Pharmaceuticals, Inc. |